Drug Profile


Alternative Names: ABBV-954; INK-1197; IPI-145

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator Intellikine
  • Developer AbbVie; Dana-Farber Cancer Institute; Infinity Pharmaceuticals; Verastem
  • Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Antirheumatics; Isoquinolines; Nonsteroidal anti-inflammatories; Purines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Phase I Haematological malignancies; Lymphoma
  • Preclinical Solid tumours
  • Discontinued Allergic asthma; Rheumatoid arthritis

Most Recent Events

  • 07 Jun 2017 Efficacy and adverse events data from a phase II trial in Non-Hodgkin's lymphoma released by Verastem
  • 01 Mar 2017 Infinity Pharmaceuticals terminates the phase III DYNAMO + R trial in Follicular lymphoma (Combination therapy, Second-line therapy or greater) in Australia, Austria, Belgium, Canada, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, New Zealand, Poland, Spain, Switzerland, United Kingdom and USA (NCT02204982) (EudraCT2013-002406-31)
  • 01 Feb 2017 AbbVie completes a phase I trial in Lymphoma (In adults, In the elderly) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top